BSX Earnings Prediction
The chart below shows how BSX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BSX sees a -3.23% change in stock price 10 days leading up to the earnings, and a +0.58% change 10 days following the report. On the earnings day itself, the stock moves by +1.72%. This data can give you a slight idea of what to expect for the next quarter's release.
BSX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
4.21B
19.34%
2.16%
Gross Margin
64.15%
1.73%
0.11%
Operating Margin
22.38%
28.33%
13.95%
Net Margin
11.12%
-22.18%
42.20%
EPS
0.32
-5.88%
45.45%
No Data Available
BSX Earnings Analysis
Boston Scientific Corp Corporation (BSX.N) Earnings Conference Call
Positive
Sales Growth Exceeds Expectations: Total company operational sales grew 19% and organic sales grew 18%, exceeding the high end of guidance range of 13% to 15%.
Earnings Per Share Growth: Q3 adjusted EPS of $0.63 grew 27%, exceeding the high end of guidance range of $0.57 to $0.59.
Strong Operational Growth: U.S. operational growth was 24%, with double-digit growth in 6 of 8 business units, highlighting strong performance across the portfolio.
Electrophysiology Sales Surge: Electrophysiology sales grew an exceptional 177% in the quarter, driven by increased procedure volumes and successful commercial execution.
Strong Free Cash Flow: Free cash flow for Q3 was $822 million, with full year expectations to exceed $2 billion, indicating strong financial health and operational efficiency.
Negative
Adjusted Gross Margin Update: Adjusted gross margin for Q3 was 70.4%, slightly lower than anticipated, driven primarily by foreign exchange, and full year adjusted gross margin is expected to be slightly below the 2023 rate.
Free Cash Flow Analysis: Free cash flow for Q3 was $822 million, with $1.2 billion from operating activities, less $180 million in net capital expenditures, indicating significant cash outflow related to acquisitions and special items.
Tax Rate Analysis: The operational tax rate for Q3 was 13.5%, and the adjusted tax rate was 13.2%, which includes favorable discrete tax items, suggesting potential volatility in future tax obligations.
Increased Interest Expense Outlook: The company expects a meaningful increase in adjusted net interest expense in 2025, with approximately $1.6 billion of bonds coming due, likely to be refinanced at higher rates than existing bonds.
Procedure Volume Slowdown: Despite strong overall performance, the company noted a slowdown in procedure volumes during July and August, indicating potential challenges in maintaining growth momentum.
BSX FAQs
How does BSX typically perform around its earnings report dates?
Is Earnings call transcript: Boston Scientific Q3 2024 shows strong growth positive or negative?
How can historical earnings data help predict future stock performance?
BSX Earning Call Sentiment
Earnings call transcript: Boston Scientific Q3 2024 shows strong growth
BSX.N
0.32%Positive
The earnings call indicates strong financial performance, with revenue and EPS growth exceeding expectations. The company has raised guidance, indicating optimism. Despite some regulatory and competitive risks, the management's confidence in product performance and upcoming launches is reassuring. The shareholder return plan includes share repurchases, which are positive. While there are concerns about supply chain and competitive pressures, the overall sentiment is positive, supported by strong operational sales and EPS growth.